FEEDENvue Medical, Inc.vs its industry peers
A metric-by-metric comparison of ENvue Medical, Inc. against SIC 3842 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FEEDEsta | $10M#6 | — | 0.3x#2 | 3.8x#4 | -0.2%#6 | -390.8%#7 | -896.6%#6 | -59.1%#4 | -74.0%#1 | — | -98.9%#3 | — |
| COCH | $56M#1 | — | 17.1x#7 | 233.8x#7 | 7.1%#3 | -14.2%#5 | -9240.7%#7 | -719.2%#7 | — | — | — | 3.2%#1 |
| APT | $53M#2 | 13.4x#1 | 0.8x#3 | 0.9x#2 | 2.3%#5 | -10.3%#4 | 6.5%#1 | 5.4%#2 | — | — | 8.2%#2 | — |
| MYO | $50M#3 | — | 8.5x#5 | 1.2x#3 | 25.7%#1 | -151.6%#6 | -35.2%#2 | -267.6%#6 | — | — | 44.3%#1 | — |
| MLSS | $36M#4 | — | 10.4x#6 | 4.0x#5 | 4.0%#4 | 21.4%#2 | -63.5%#3 | 164.9%#1 | — | — | — | — |
| NTRBW | $12M#5 | — | 2.2x#4 | 5.7x#6 | -4.8%#7 | 21.5%#1 | -408.4%#5 | -154.4%#5 | -212.9%#3 | — | — | — |
| LGMK | $10077#7 | — | 0.0x#1 | 0.0x#1 | 15.4%#2 | 17.1%#3 | -69.1%#4 | -56.6%#3 | -76.3%#2 | 3#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3842). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice